Getinge AB (publ) (GETI-B.ST)
SEK 174.85
(2.01%)
SEK 174.85
(2.01%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 24.69 Billion SEK | 14.44% |
| 2022 | 21.57 Billion SEK | 11.35% |
| 2021 | 19.37 Billion SEK | -17.63% |
| 2020 | 23.52 Billion SEK | -0.89% |
| 2019 | 23.74 Billion SEK | 0.18% |
| 2018 | 23.69 Billion SEK | 6.28% |
| 2017 | 22.29 Billion SEK | -34.99% |
| 2016 | 34.29 Billion SEK | 1.94% |
| 2015 | 33.64 Billion SEK | -1.41% |
| 2014 | 34.12 Billion SEK | 23.0% |
| 2013 | 27.74 Billion SEK | 0.08% |
| 2012 | 27.72 Billion SEK | 3.31% |
| 2011 | 26.83 Billion SEK | 25.76% |
| 2010 | 21.33 Billion SEK | -14.43% |
| 2009 | 24.93 Billion SEK | 11.54% |
| 2008 | 22.35 Billion SEK | 36.58% |
| 2007 | 16.36 Billion SEK | 65.8% |
| 2006 | 9.87 Billion SEK | 7.87% |
| 2005 | 9.15 Billion SEK | 11.78% |
| 2004 | 8.18 Billion SEK | -3.69% |
| 2003 | 8.5 Billion SEK | 34.53% |
| 2002 | 6.31 Billion SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 23.71 Billion SEK | -3.97% |
| 2024 Q3 | 29.14 Billion SEK | 23.89% |
| 2024 Q2 | 23.52 Billion SEK | -0.79% |
| 2023 Q3 | 21.52 Billion SEK | -0.06% |
| 2023 Q1 | 19.92 Billion SEK | -7.66% |
| 2023 Q2 | 21.53 Billion SEK | 8.08% |
| 2023 FY | 24.69 Billion SEK | 14.44% |
| 2023 Q4 | 24.69 Billion SEK | 14.74% |
| 2022 Q2 | 20.2 Billion SEK | 6.76% |
| 2022 Q3 | 21 Billion SEK | 3.92% |
| 2022 FY | 21.57 Billion SEK | 11.35% |
| 2022 Q4 | 21.57 Billion SEK | 2.76% |
| 2022 Q1 | 18.92 Billion SEK | -2.33% |
| 2021 Q1 | 21.64 Billion SEK | -8.01% |
| 2021 Q4 | 19.37 Billion SEK | 0.02% |
| 2021 Q3 | 19.37 Billion SEK | 2.56% |
| 2021 FY | 19.37 Billion SEK | -17.63% |
| 2021 Q2 | 18.89 Billion SEK | -12.72% |
| 2020 Q2 | 28.06 Billion SEK | 9.98% |
| 2020 Q4 | 23.52 Billion SEK | -10.29% |
| 2020 FY | 23.52 Billion SEK | -0.89% |
| 2020 Q1 | 25.51 Billion SEK | 7.49% |
| 2020 Q3 | 26.22 Billion SEK | -6.55% |
| 2019 Q4 | 23.74 Billion SEK | -7.63% |
| 2019 FY | 23.74 Billion SEK | 0.18% |
| 2019 Q3 | 25.7 Billion SEK | 2.56% |
| 2019 Q2 | 25.06 Billion SEK | 1.91% |
| 2019 Q1 | 24.59 Billion SEK | 3.77% |
| 2018 Q2 | 22.79 Billion SEK | 3.66% |
| 2018 Q3 | 23.71 Billion SEK | 4.04% |
| 2018 FY | 23.69 Billion SEK | 6.28% |
| 2018 Q4 | 23.69 Billion SEK | -0.09% |
| 2018 Q1 | 21.99 Billion SEK | -1.37% |
| 2017 Q1 | 34.17 Billion SEK | -0.34% |
| 2017 Q4 | 22.29 Billion SEK | -20.09% |
| 2017 Q3 | 27.9 Billion SEK | -14.88% |
| 2017 Q2 | 32.77 Billion SEK | -4.1% |
| 2017 FY | 22.29 Billion SEK | -34.99% |
| 2016 Q4 | 34.29 Billion SEK | -2.01% |
| 2016 Q3 | 34.99 Billion SEK | 1.21% |
| 2016 Q1 | 33.27 Billion SEK | -1.09% |
| 2016 FY | 34.29 Billion SEK | 1.94% |
| 2016 Q2 | 34.57 Billion SEK | 3.92% |
| 2015 Q1 | 36.98 Billion SEK | 8.37% |
| 2015 FY | 33.64 Billion SEK | -1.41% |
| 2015 Q4 | 33.64 Billion SEK | -3.05% |
| 2015 Q3 | 34.7 Billion SEK | 0.28% |
| 2015 Q2 | 34.6 Billion SEK | -6.42% |
| 2014 Q2 | 30.66 Billion SEK | 2.46% |
| 2014 Q1 | 29.92 Billion SEK | 7.87% |
| 2014 FY | 34.12 Billion SEK | 23.0% |
| 2014 Q4 | 34.12 Billion SEK | 6.95% |
| 2014 Q3 | 31.9 Billion SEK | 4.06% |
| 2013 Q3 | 27.89 Billion SEK | -4.42% |
| 2013 Q2 | 29.18 Billion SEK | 4.94% |
| 2013 Q1 | 27.8 Billion SEK | 0.32% |
| 2013 FY | 27.74 Billion SEK | 0.08% |
| 2013 Q4 | 27.74 Billion SEK | -0.54% |
| 2012 Q1 | 24.98 Billion SEK | -6.91% |
| 2012 Q2 | 26.54 Billion SEK | 6.25% |
| 2012 Q3 | 26.06 Billion SEK | -1.8% |
| 2012 FY | 27.72 Billion SEK | 3.31% |
| 2012 Q4 | 27.72 Billion SEK | 6.37% |
| 2011 Q1 | 20.03 Billion SEK | -6.11% |
| 2011 Q4 | 26.83 Billion SEK | 25.81% |
| 2011 FY | 26.83 Billion SEK | 25.76% |
| 2011 Q3 | 21.32 Billion SEK | 4.12% |
| 2011 Q2 | 20.48 Billion SEK | 2.26% |
| 2010 Q1 | 23.7 Billion SEK | -4.95% |
| 2010 FY | 21.33 Billion SEK | -14.43% |
| 2010 Q4 | 21.33 Billion SEK | -3.66% |
| 2010 Q3 | 22.14 Billion SEK | -10.5% |
| 2010 Q2 | 24.74 Billion SEK | 4.41% |
| 2009 Q4 | 24.93 Billion SEK | 0.0% |
| 2009 FY | 24.93 Billion SEK | 11.54% |
| 2008 FY | 22.35 Billion SEK | 36.58% |
| 2007 FY | 16.36 Billion SEK | 65.8% |
| 2006 FY | 9.87 Billion SEK | 7.87% |
| 2005 FY | 9.15 Billion SEK | 11.78% |
| 2004 FY | 8.18 Billion SEK | -3.69% |
| 2003 FY | 8.5 Billion SEK | 34.53% |
| 2002 FY | 6.31 Billion SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -224449.918% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | -823.491% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | -823.491% |
| Arcoma AB | 33.3 Million SEK | -74051.028% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | -7390.446% |
| BICO Group AB (publ) | 3.26 Billion SEK | -656.479% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | -8723.151% |
| CellaVision AB (publ) | 212.32 Million SEK | -11531.335% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -173852.243% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -359431.508% |
| C-Rad AB (publ) | 122.4 Million SEK | -20076.471% |
| Duearity AB (publ) | 17.53 Million SEK | -140778.494% |
| Dignitana AB (publ) | 37.56 Million SEK | -65638.547% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -124627.273% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -119781.72% |
| Iconovo AB (publ) | 14.55 Million SEK | -169586.557% |
| Integrum AB (publ) | 22.07 Million SEK | -111783.996% |
| Luxbright AB (publ) | 7 Million SEK | -352693.952% |
| Mentice AB (publ) | 163.55 Million SEK | -14999.6% |
| OssDsign AB (publ) | 105.25 Million SEK | -23362.573% |
| Paxman AB (publ) | 44.5 Million SEK | -55385.407% |
| Promimic AB (publ) | 16.15 Million SEK | -152759.628% |
| Qlife Holding AB (publ) | 62.16 Million SEK | -39623.978% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -115963.54% |
| ScandiDos AB (publ) | 37.18 Million SEK | -66312.091% |
| Sectra AB (publ) | 1.64 Billion SEK | -1404.618% |
| Sedana Medical AB (publ) | 44.06 Million SEK | -55948.296% |
| Senzime AB (publ) | 58.06 Million SEK | -42431.646% |
| SpectraCure AB (publ) | 14.97 Million SEK | -164814.858% |
| Stille AB | 172.64 Million SEK | -14204.912% |
| Vitrolife AB (publ) | 3.66 Billion SEK | -573.282% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | -9756.086% |